Prospective trials recruiting after CAR T-cell therapy
| Trial . | Therapy . | Clinical trial info . |
|---|---|---|
| SWOG | Mosunetuzumab ± polatuzumab | NCT05633615 |
| ALPHA2 | ALLO-501A CD19 allo CAR | NCT04416984 |
| PBCAR0191 | CD19 allo CAR | NCT03666000 |
| ANTLER CB-010 | CRISPR edited CD19 allo CAR | NCT 04637763 |
| TAK-007 | CD19 allo natural killer CAR | NCT05020015 |
| Phase 1/2 CD20 CAR T | CD20-specific CAR T cell | NCT03277729 |
| Phase 1/2 CD19/20 CAR T | CD19/CD20 CAR T cell | NCT04186520 |
| KITE-363, phase 1 | CD19/CD20 CAR T cell | NCT04989803 |
| JV-213, phase 1, | CD79b CAR T cell | NCT05773040 |
| Phase 2/3, NKTR-255 vs placebo following CD19 CAR T-cell therapy | NKTR-255 (IL-15 receptor agonist) | NCT05664217 |
| Trial . | Therapy . | Clinical trial info . |
|---|---|---|
| SWOG | Mosunetuzumab ± polatuzumab | NCT05633615 |
| ALPHA2 | ALLO-501A CD19 allo CAR | NCT04416984 |
| PBCAR0191 | CD19 allo CAR | NCT03666000 |
| ANTLER CB-010 | CRISPR edited CD19 allo CAR | NCT 04637763 |
| TAK-007 | CD19 allo natural killer CAR | NCT05020015 |
| Phase 1/2 CD20 CAR T | CD20-specific CAR T cell | NCT03277729 |
| Phase 1/2 CD19/20 CAR T | CD19/CD20 CAR T cell | NCT04186520 |
| KITE-363, phase 1 | CD19/CD20 CAR T cell | NCT04989803 |
| JV-213, phase 1, | CD79b CAR T cell | NCT05773040 |
| Phase 2/3, NKTR-255 vs placebo following CD19 CAR T-cell therapy | NKTR-255 (IL-15 receptor agonist) | NCT05664217 |